Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Transglutaminase 2 takes center stage as a cancer cell survival factor and therapy target

29 Jan 2019

Abstract excerpt

Transglutaminase 2 (TG2) has emerged as a key cancer cell survival factor that drives epithelial to mesenchymal transition, angiogenesis, metastasis, inflammation, drug resistance, cancer stem cell survival and stemness, and invasion and migration. TG2 can exist in a GTP-bound signaling-active conformation or in a transamidase-active conformation. The GTP bound conformation of TG2 contributes to cell survival and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood properties and coagulation
Share to Erythrocyte Function and Pathophysiology
Share to Platelet Disorders and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30693974
DOI: 10.1002/mc.22986

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Transglutaminase 2 takes center stage as a cancer cell survival factor and therapy targetPMID 30693974Read ↗

The Role of Transglutaminase 2 in Cancer: An UpdateSemantic proximity Read ↗

Tissue transglutaminase: a new target to reverse cancer drug resistanceSemantic proximity Read ↗

Evidence that GTP-binding domain but not catalytic domain of transglutaminase 2 is essential for epithelial-to-mesenchymal transition in mammary epithelial cells.Semantic proximity Read ↗

Transglutaminase 2 promotes tumorigenicity of colon cancer cells by inactivation of the tumor suppressor p53Semantic proximity Read ↗

Transglutaminases are oncogenic biomarkers in human cancers and therapeutic targeting of TGM2 blocks chemoresistance and macrophage infiltration in pancreatic cancerSemantic proximity Read ↗

Cell-Impermeable Inhibitors Confirm That Intracellular Human Transglutaminase 2 Is Responsible for the Transglutaminase-Associated Cancer Phenotype.Semantic proximity Read ↗

The Biological and Biomechanical Role of Transglutaminase-2 in the Tumour MicroenvironmentSemantic proximity Read ↗

Tissue transglutaminase: from biological glue to cell survival cues.Semantic proximity Read ↗

The complex role of transglutaminase 2 in glioblastoma proliferationSemantic proximity Read ↗

TGM2 and implications for human disease: role of alternative splicingSemantic proximity Read ↗

The transglutaminase 2 cancer cell survival factor maintains mTOR activity to drive an aggressive cancer phenotype.Semantic proximity Read ↗

Transglutaminase 2 Maintains Hepatocyte Growth Factor Signaling to Enhance the Cancer Cell Phenotype.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.